A 1-year follow-up of a multi-center treatment trial of adults with anorexia nervosa

Eat Weight Disord. 2011 Sep;16(3):e177-81. doi: 10.1007/BF03325129.

Abstract

Objective: To examine maintenance of recovery following treatment in an adult anorexia nervosa (AN) population.

Method: One year follow-up of a randomized clinical trial with 122 participants treated with: cognitive behavioral therapy (CBT), drug therapy (fluoxetine), or a combination (CBT+fluoxetine) for 12 months. Participants were assessed at baseline, end of treatment, and follow-up. The primary outcomes were weight and the global scores from the Eating Disorder Examination (EDE) separately and combined.

Results: Fifty-two participants completed the follow-up. Mean weight increased from end of treatment to follow-up. Seventy-five percent (75%) of those weight recovered at end of treatment maintained this recovery at follow-up. Recovery of eating disorder psychopathology was stable from end of treatment to follow-up, with 40% of participants with a global EDE score within normal range. Using the most stringent criteria for recovery, only 21% of the completer sample was recovered.

Discussion: The findings suggest that while adults with AN improve with treatment and maintain these improvements during follow-up, the majority is not recovered. Additionally, further research is needed to understand barriers to treatment and assessment completion.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anorexia Nervosa / drug therapy
  • Anorexia Nervosa / psychology
  • Anorexia Nervosa / therapy*
  • Body Weight
  • Cognitive Behavioral Therapy*
  • Combined Modality Therapy
  • Female
  • Fluoxetine / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Personality
  • Psychiatric Status Rating Scales
  • Selective Serotonin Reuptake Inhibitors / therapeutic use*
  • Self Concept
  • Surveys and Questionnaires
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors
  • Fluoxetine